Favorable News Coverage Extremely Likely to Affect Ariad Pharmaceuticals (ARIA) Stock Price
News articles about Ariad Pharmaceuticals (NASDAQ:ARIA) have trended positive on Thursday, according to AlphaOne Sentiment. The research group, a service of Accern, ranks the sentiment of media coverage by analyzing more than twenty million blog and news sources. AlphaOne ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Ariad Pharmaceuticals earned a coverage optimism score of 0.44 on AlphaOne’s scale. AlphaOne also gave media headlines about the pharmaceutical company an impact score of 100 out of 100, meaning that recent media coverage is extremely likely to have an effect on the company’s share price in the next several days.
These are some of the media headlines that may have impacted Alpha One’s scoring:
- Seabridge Investment Advisors Has Increased By $3.64 Million Its … – High Point Observer (highpointobserver.com)
- North America Uterine Cancer Therapeutics Market growing at a CAGR of 4.98% during the forecast period 2016-2021 (emailwire.com)
- Seabridge Investment Advisors Has Increased By $3.64 Million Its Ares Capital (ARCC) Stake, 0 Bullish Analysts … – High Point Observer (highpointobserver.com)
- Middle East and Africa Uterine Cancer Therapeutics Market: Admission of New Products to Create Growth Opportunities for Players (emailwire.com)
- Monday Is D-Day For AEZS, Watch Out For MRUS, FDA Nod For RDUS & Takeda (nasdaq.com)
Shares of Ariad Pharmaceuticals (NASDAQ:ARIA) opened at 23.99 on Thursday. Ariad Pharmaceuticals has a 1-year low of $4.67 and a 1-year high of $23.99. The stock has a 50 day moving average price of $21.86 and a 200 day moving average price of $14.14.
ARIA has been the topic of several research analyst reports. Zacks Investment Research cut Ariad Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, January 27th. Jefferies Group LLC cut Ariad Pharmaceuticals from a “buy” rating to a “hold” rating and increased their price target for the company from $11.00 to $24.00 in a report on Tuesday, January 10th. Leerink Swann cut Ariad Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Tuesday, January 10th. Barclays PLC raised Ariad Pharmaceuticals from an “underweight” rating to an “equal weight” rating and increased their price target for the company from $9.00 to $24.00 in a report on Tuesday, January 10th. Finally, Cowen and Company reissued a “buy” rating and set a $16.00 price target on shares of Ariad Pharmaceuticals in a report on Tuesday, January 10th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and two have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $17.59.
Ariad Pharmaceuticals Company Profile
ARIAD Pharmaceuticals, Inc (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company’s product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company’s Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Receive News & Ratings for Ariad Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ariad Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.